At MD Anderson, we work in partnership with our patients to enable groundbreaking research to better prevent, diagnose and treat cancer. Grounded in a culture of collaboration, connectivity, and data-based science, our research yields transformative findings that are shifting patient care and improving patients’ lives across the globe.
At the 2023 American Society of Clinical Oncology Annual Meeting, our experts will showcase their pacesetting research and join colleagues for discussion on the latest advances in oncology.
Below are highlights from our presentations, details about onsite networking opportunities with our experts and information on open positions at MD Anderson.
Featured Articles
The next generation of CDK inhibitors is coming
MD Anderson researchers remain focused on studying and developing CDK inhibitors. Soon, new research may solve the issues of the original CDK4/6 inhibitors and help these therapies reach even more patients.
Luspatercept enables majority of patients with MDS to end reliance on blood transfusions
MD Anderson-led COMMANDS trial showed improved red blood cell counts and erythroid responses in transfusion-dependent patients.
MD Anderson Research Highlights: ASCO 2023 Special Edition
Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. This special edition features presentations by MD Anderson researchers at the ASCO Annual Meeting that will share novel treatments for ALL, CRC, melanoma, EGFR and KRAS mutations, as well as reduced racial disparities in GI cancers.
MD Anderson’s Hagop Kantarjian, M.D., awarded highest honor from American Society of Clinical Oncology
Kantarjian to receive David A. Karnofsky Memorial Award for lifelong contributions to leukemia research and patient care
Meet the Experts
Visit booth 14030 to meet our experts and discuss hot topics in cancer research, learn about training and career opportunities and continue the conversation on key presentations. See the full schedule below.
Saturday, June 3
11:30 a.m.–12 p.m.
Advances in neoadjuvant therapies/immunotherapies
Rodabe Amaria, M.D.
Tina Cascone, M.D., Ph.D.
Jianjun Gao, M.D., Ph.D.
Sapna Patel, M.D.
12:30–1 p.m.
Insights on pediatric and adolescent and young adult care
1–4 p.m.
Peter WT Pisters, M.D.
MD Anderson President
2:30–3:30 p.m.
Physician wellness: MD Anderson’s culture of caring
3–4 p.m.
4:30–5 p.m.
Hagop Kantarjian, M.D.
David A. Karnofsky Memorial Award honoree
Sunday, June 4
9–9:30 a.m.
Accelerating research with industry collaborations
Jean Gilbert
Timothy Heffernan, Ph.D.
Timothy Yap, M.B.B.S., Ph.D.
10–10:45 a.m.
Immunotherapy: Novel combinations to improve results
10:45–11:15 a.m.
Minimal residual disease: Detection and treatment advances
11:30 a.m.–12 p.m.
Brain metastasis and the latest treatments
Monday, June 5
9–9:30 a.m.
12–1 p.m.
1–1:30 p.m.
Targeting cancer vulnerabilities: DDR and RAS
2:30–3 p.m.
2:45–3:15 p.m.
The interception of precancers
James P. Allison Institute
The James P. Allison Institute is dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.
Why Houston?
As America's fourth-largest city, Houston has a lot to offer. Find out why Houston is a hub for scientific and medical excellence.
Our research by the numbers
$1B+
invested in research
1,680
clinical trials
116
patents awarded
From Sept. 1, 2021-Aug. 31, 2022.
Education and Training at MD Anderson
MD Anderson academic programs are competitive and comprehensive. We offer educational opportunities for learners at all levels, from programs for high school students and undergraduate degrees to graduate medical education and postdoctoral fellowships.